Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 95,179 shares at $1.01 ($95K) on 2025-12-09, disclosed to the SEC on 2025-12-09.
Scheduled sale ($95k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.97 | 16,568 | $16K | 17.0% |
| 2 | $0.99 | 34,041 | $34K | 35.6% |
| 3 | $1.01 | 44,570 | $45K | 47.5% |
| Total | $1.00 avg | 95,179 | $95K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |